Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

Key Points

• Lifesci Capital has lowered its Q1 2026 earnings estimate for Zymeworks, now predicting $0.47 per share compared to a previous estimate of $0.49.
• Zymeworks reported revenue of $48.73 million for the recent quarter, significantly exceeding analyst estimates of $17.18 million, and had a 153.2% increase in revenue compared to the same quarter last year.
• Insider activity has seen Ecor1 Capital acquire 49,502 shares at an average cost of $11.43 per share, increasing their ownership in Zymeworks.

Zymeworks Inc. (NYSE:ZYME - Free Report) - Investment analysts at Lifesci Capital decreased their Q1 2026 earnings per share estimates for Zymeworks in a report issued on Thursday, August 7th. Lifesci Capital analyst C. Zhu now forecasts that the company will earn $0.47 per share for the quarter, down from their previous estimate of $0.49. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share.

Several other research firms have also weighed in on ZYME. TD Cowen assumed coverage on Zymeworks in a research note on Tuesday, May 20th. They issued a "buy" rating on the stock. TD Securities initiated coverage on Zymeworks in a report on Tuesday, May 20th. They issued a "buy" rating for the company. Finally, HC Wainwright restated a "neutral" rating and issued a $13.00 price target on shares of Zymeworks in a report on Thursday, July 3rd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $21.00.

Zymeworks Trading Down 1.2%

NYSE:ZYME opened at $12.02 on Monday. Zymeworks has a 1-year low of $9.03 and a 1-year high of $17.70. The business's 50-day moving average price is $12.92 and its two-hundred day moving average price is $12.67. The firm has a market capitalization of $837.59 million, a price-to-earnings ratio of -8.01 and a beta of 1.26.

Zymeworks (NYSE:ZYME - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.55. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The business had revenue of $48.73 million for the quarter, compared to analyst estimates of $17.18 million. During the same quarter in the prior year, the firm posted ($0.49) earnings per share. The firm's revenue for the quarter was up 153.2% compared to the same quarter last year.

Insider Activity

In other news, Director Ecor1 Capital, Llc acquired 49,502 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was acquired at an average cost of $11.43 per share, for a total transaction of $565,807.86. Following the completion of the acquisition, the director owned 17,877,989 shares in the company, valued at $204,345,414.27. This represents a 0.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.92% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Sterling Capital Management LLC grew its holdings in shares of Zymeworks by 781.5% during the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after buying an additional 1,524 shares in the last quarter. CWM LLC grew its stake in Zymeworks by 1,091.2% in the first quarter. CWM LLC now owns 2,299 shares of the company's stock valued at $27,000 after purchasing an additional 2,106 shares in the last quarter. GAMMA Investing LLC grew its stake in Zymeworks by 1,113.3% in the first quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock valued at $77,000 after purchasing an additional 5,934 shares in the last quarter. BNP Paribas Financial Markets bought a new position in Zymeworks in the fourth quarter valued at approximately $108,000. Finally, Northwest & Ethical Investments L.P. grew its stake in Zymeworks by 83.3% in the first quarter. Northwest & Ethical Investments L.P. now owns 10,030 shares of the company's stock valued at $119,000 after purchasing an additional 4,559 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors.

About Zymeworks

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.